Background Little is known about drug adherence in men treated for lower urinary tract
symptoms (LUTS). Benign prostatic hyperplasia (BPH) is one of the causes of LUTS …

Background Recent studies showed that the non-adherence to the pharmacological therapy
of patients affected by BPH-associated LUTS increased the risk of clinical progression of …

PURPOSE: We investigated adherence to benign prostatic hyperplasia medications in a
California Medicaid population. MATERIALS AND METHODS: Using California Medicaid …

Objectives: We aimed to describe treatment strategies for lower urinary tract symptoms
suggestive of benign prostatic hyperplasia (LUTS/BPH), adherence to and persistence with …

Objective: To investigate whether there is a difference in the risk of progressing to BPH-
related prostatic surgery between patients using alpha-blockers and patients using the 5 …

Background Male lower urinary tract symptoms (LUTS) are one of the most treated diseases,
but little is known about patient trajectories in current clinical practice. Objective To describe …

Abstract Context Alpha-blockers (ABs) and 5-alpha reductase inhibitors have an established
role in treating male lower urinary tract symptoms (LUTS) attributed to benign prostatic …

BACKGROUND: The estimated prevalence of lower urinary tract symptoms (LUTS) related
to benign prostatic hyperplasia (BPH) in men> 50 yr of age is around 30%, similar in all …

Benign prostatic hyperplasia (BPH) is a complex disease that is progressive in many men.
BPH is commonly associated with bothersome lower urinary tract symptoms; progressive …

Comparative Effectiveness and Safety of Monodrug Therapies f... : Medicine Comparative
Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated …